nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—BRAF—hematologic cancer	0.177	0.614	CbGaD
Dabrafenib—ABCG2—hematologic cancer	0.0787	0.273	CbGaD
Dabrafenib—LOC102724428—Dasatinib—hematologic cancer	0.075	0.18	CbGbCtD
Dabrafenib—SIK1—Dasatinib—hematologic cancer	0.075	0.18	CbGbCtD
Dabrafenib—BRAF—Nilotinib—hematologic cancer	0.0564	0.135	CbGbCtD
Dabrafenib—ABCB1—hematologic cancer	0.0328	0.114	CbGaD
Dabrafenib—ABCG2—Clofarabine—hematologic cancer	0.0157	0.0375	CbGbCtD
Dabrafenib—ABCG2—Daunorubicin—hematologic cancer	0.00919	0.022	CbGbCtD
Dabrafenib—SLC22A8—Mercaptopurine—hematologic cancer	0.00827	0.0198	CbGbCtD
Dabrafenib—ABCG2—Teniposide—hematologic cancer	0.00798	0.0191	CbGbCtD
Dabrafenib—ABCG2—Cladribine—hematologic cancer	0.00765	0.0183	CbGbCtD
Dabrafenib—ABCG2—Imatinib—hematologic cancer	0.00704	0.0168	CbGbCtD
Dabrafenib—ABCG2—Nilotinib—hematologic cancer	0.00639	0.0153	CbGbCtD
Dabrafenib—ABCG2—Dasatinib—hematologic cancer	0.00565	0.0135	CbGbCtD
Dabrafenib—ABCB1—Lenalidomide—hematologic cancer	0.00565	0.0135	CbGbCtD
Dabrafenib—ABCG2—Mitoxantrone—hematologic cancer	0.00558	0.0134	CbGbCtD
Dabrafenib—SLCO1B1—Irinotecan—hematologic cancer	0.00553	0.0132	CbGbCtD
Dabrafenib—CYP2C8—Bortezomib—hematologic cancer	0.00512	0.0122	CbGbCtD
Dabrafenib—SLCO1B3—Methotrexate—hematologic cancer	0.00503	0.012	CbGbCtD
Dabrafenib—ABCG2—Irinotecan—hematologic cancer	0.00439	0.0105	CbGbCtD
Dabrafenib—CYP2C8—Ifosfamide—hematologic cancer	0.00392	0.00939	CbGbCtD
Dabrafenib—ABCG2—Vincristine—hematologic cancer	0.00384	0.0092	CbGbCtD
Dabrafenib—ABCG2—Cisplatin—hematologic cancer	0.00358	0.00858	CbGbCtD
Dabrafenib—ABCG2—Etoposide—hematologic cancer	0.00352	0.00843	CbGbCtD
Dabrafenib—CYP2C8—Nilotinib—hematologic cancer	0.00341	0.00815	CbGbCtD
Dabrafenib—CYP3A4—Bexarotene—hematologic cancer	0.00338	0.0081	CbGbCtD
Dabrafenib—ABCB1—Daunorubicin—hematologic cancer	0.00331	0.00793	CbGbCtD
Dabrafenib—ABCB1—Alitretinoin—hematologic cancer	0.00324	0.00777	CbGbCtD
Dabrafenib—CYP3A4—Busulfan—hematologic cancer	0.00315	0.00753	CbGbCtD
Dabrafenib—CYP3A4—Lomustine—hematologic cancer	0.00315	0.00753	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—hematologic cancer	0.00293	0.00701	CbGbCtD
Dabrafenib—ABCG2—Dexamethasone—hematologic cancer	0.00289	0.00693	CbGbCtD
Dabrafenib—CYP3A4—Thiotepa—hematologic cancer	0.0028	0.00672	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—hematologic cancer	0.0027	0.00647	CbGbCtD
Dabrafenib—ABCB1—Imatinib—hematologic cancer	0.00254	0.00607	CbGbCtD
Dabrafenib—ABCG2—Doxorubicin—hematologic cancer	0.0024	0.00575	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—hematologic cancer	0.00233	0.00557	CbGbCtD
Dabrafenib—ABCB1—Nilotinib—hematologic cancer	0.00231	0.00552	CbGbCtD
Dabrafenib—ABCB1—Vinorelbine—hematologic cancer	0.00229	0.00547	CbGbCtD
Dabrafenib—CYP3A4—Methoxsalen—hematologic cancer	0.00218	0.00522	CbGbCtD
Dabrafenib—NEK11—lung—hematologic cancer	0.00215	0.0653	CbGeAlD
Dabrafenib—CYP3A4—Bortezomib—hematologic cancer	0.00207	0.00497	CbGbCtD
Dabrafenib—ABCB1—Dasatinib—hematologic cancer	0.00204	0.00488	CbGbCtD
Dabrafenib—NEK11—testis—hematologic cancer	0.00203	0.0616	CbGeAlD
Dabrafenib—ABCB1—Mitoxantrone—hematologic cancer	0.00201	0.00482	CbGbCtD
Dabrafenib—CYP3A4—Daunorubicin—hematologic cancer	0.00198	0.00475	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—hematologic cancer	0.00188	0.00451	CbGbCtD
Dabrafenib—CYP2C8—Etoposide—hematologic cancer	0.00188	0.00449	CbGbCtD
Dabrafenib—ABCB1—Betamethasone—hematologic cancer	0.00179	0.0043	CbGbCtD
Dabrafenib—ABCB1—Gemcitabine—hematologic cancer	0.00178	0.00426	CbGbCtD
Dabrafenib—ABCB1—Prednisolone—hematologic cancer	0.00177	0.00424	CbGbCtD
Dabrafenib—LIMK1—blood—hematologic cancer	0.00175	0.0533	CbGeAlD
Dabrafenib—CYP3A4—Cytarabine—hematologic cancer	0.00175	0.00419	CbGbCtD
Dabrafenib—CYP3A4—Teniposide—hematologic cancer	0.00172	0.00413	CbGbCtD
Dabrafenib—RAF1—Topotecan—Irinotecan—hematologic cancer	0.00168	1	CbGdCrCtD
Dabrafenib—ABCB1—Prednisone—hematologic cancer	0.00167	0.004	CbGbCtD
Dabrafenib—CYP3A4—Ifosfamide—hematologic cancer	0.00159	0.00381	CbGbCtD
Dabrafenib—ABCB1—Irinotecan—hematologic cancer	0.00158	0.00379	CbGbCtD
Dabrafenib—CYP2C8—Dexamethasone—hematologic cancer	0.00154	0.00369	CbGbCtD
Dabrafenib—CYP3A4—Imatinib—hematologic cancer	0.00152	0.00364	CbGbCtD
Dabrafenib—NEK11—lymph node—hematologic cancer	0.00147	0.0447	CbGeAlD
Dabrafenib—LIMK1—testis—hematologic cancer	0.00145	0.0441	CbGeAlD
Dabrafenib—CYP3A4—Ruxolitinib—hematologic cancer	0.00143	0.00343	CbGbCtD
Dabrafenib—ABCB1—Vinblastine—hematologic cancer	0.00141	0.00337	CbGbCtD
Dabrafenib—ABCB1—Vincristine—hematologic cancer	0.00139	0.00332	CbGbCtD
Dabrafenib—CYP3A4—Nilotinib—hematologic cancer	0.00138	0.00331	CbGbCtD
Dabrafenib—CYP3A4—Vinorelbine—hematologic cancer	0.00137	0.00328	CbGbCtD
Dabrafenib—SIK1—hematopoietic system—hematologic cancer	0.00137	0.0416	CbGeAlD
Dabrafenib—ABCB1—Cisplatin—hematologic cancer	0.00129	0.00309	CbGbCtD
Dabrafenib—ABCB1—Etoposide—hematologic cancer	0.00127	0.00304	CbGbCtD
Dabrafenib—CYP3A4—Triamcinolone—hematologic cancer	0.00125	0.003	CbGbCtD
Dabrafenib—CYP3A4—Dasatinib—hematologic cancer	0.00122	0.00292	CbGbCtD
Dabrafenib—CYP3A4—Mitoxantrone—hematologic cancer	0.00121	0.00289	CbGbCtD
Dabrafenib—RAF1—hematopoietic system—hematologic cancer	0.00109	0.0331	CbGeAlD
Dabrafenib—BRAF—blood—hematologic cancer	0.00108	0.0329	CbGeAlD
Dabrafenib—CYP3A4—Betamethasone—hematologic cancer	0.00107	0.00257	CbGbCtD
Dabrafenib—CYP3A4—Prednisolone—hematologic cancer	0.00106	0.00254	CbGbCtD
Dabrafenib—LIMK1—lymph node—hematologic cancer	0.00105	0.032	CbGeAlD
Dabrafenib—BRAF—bone marrow—hematologic cancer	0.00105	0.0319	CbGeAlD
Dabrafenib—ABCB1—Dexamethasone—hematologic cancer	0.00104	0.0025	CbGbCtD
Dabrafenib—SIK1—gonad—hematologic cancer	0.00104	0.0317	CbGeAlD
Dabrafenib—CYP3A4—Prednisone—hematologic cancer	0.001	0.0024	CbGbCtD
Dabrafenib—BRAF—lung—hematologic cancer	0.00095	0.0289	CbGeAlD
Dabrafenib—CYP3A4—Irinotecan—hematologic cancer	0.000949	0.00227	CbGbCtD
Dabrafenib—SIK1—blood—hematologic cancer	0.000907	0.0276	CbGeAlD
Dabrafenib—BRAF—testis—hematologic cancer	0.000896	0.0273	CbGeAlD
Dabrafenib—SIK1—bone marrow—hematologic cancer	0.000877	0.0267	CbGeAlD
Dabrafenib—ABCB1—Doxorubicin—hematologic cancer	0.000866	0.00207	CbGbCtD
Dabrafenib—CYP3A4—Vinblastine—hematologic cancer	0.000844	0.00202	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—hematologic cancer	0.000839	0.00201	CbGbCtD
Dabrafenib—CYP3A4—Vincristine—hematologic cancer	0.00083	0.00199	CbGbCtD
Dabrafenib—RAF1—gonad—hematologic cancer	0.000828	0.0252	CbGeAlD
Dabrafenib—SLCO1B3—lung—hematologic cancer	0.000818	0.0249	CbGeAlD
Dabrafenib—SLCO1B1—hematopoietic system—hematologic cancer	0.000815	0.0248	CbGeAlD
Dabrafenib—SIK1—lung—hematologic cancer	0.000795	0.0242	CbGeAlD
Dabrafenib—CYP3A4—Etoposide—hematologic cancer	0.00076	0.00182	CbGbCtD
Dabrafenib—SIK1—testis—hematologic cancer	0.00075	0.0228	CbGeAlD
Dabrafenib—RAF1—blood—hematologic cancer	0.000722	0.022	CbGeAlD
Dabrafenib—RAF1—bone marrow—hematologic cancer	0.000698	0.0212	CbGeAlD
Dabrafenib—BRAF—lymph node—hematologic cancer	0.000649	0.0198	CbGeAlD
Dabrafenib—SLC22A8—hematopoietic system—hematologic cancer	0.000633	0.0193	CbGeAlD
Dabrafenib—RAF1—lung—hematologic cancer	0.000633	0.0192	CbGeAlD
Dabrafenib—CYP3A4—Dexamethasone—hematologic cancer	0.000625	0.0015	CbGbCtD
Dabrafenib—RAF1—testis—hematologic cancer	0.000597	0.0182	CbGeAlD
Dabrafenib—SIK1—lymph node—hematologic cancer	0.000544	0.0165	CbGeAlD
Dabrafenib—SLCO1B1—blood—hematologic cancer	0.00054	0.0164	CbGeAlD
Dabrafenib—CYP3A4—Doxorubicin—hematologic cancer	0.000519	0.00124	CbGbCtD
Dabrafenib—CYP2C8—hematopoietic system—hematologic cancer	0.000463	0.0141	CbGeAlD
Dabrafenib—RAF1—lymph node—hematologic cancer	0.000433	0.0132	CbGeAlD
Dabrafenib—SLC22A8—blood—hematologic cancer	0.00042	0.0128	CbGeAlD
Dabrafenib—CYP3A4—hematopoietic system—hematologic cancer	0.000314	0.00955	CbGeAlD
Dabrafenib—CYP2C8—blood—hematologic cancer	0.000307	0.00934	CbGeAlD
Dabrafenib—ABCG2—blood—hematologic cancer	0.000299	0.00908	CbGeAlD
Dabrafenib—ABCG2—bone marrow—hematologic cancer	0.000289	0.00879	CbGeAlD
Dabrafenib—ABCG2—lung—hematologic cancer	0.000262	0.00796	CbGeAlD
Dabrafenib—CYP2C8—testis—hematologic cancer	0.000254	0.00773	CbGeAlD
Dabrafenib—ABCG2—testis—hematologic cancer	0.000247	0.00751	CbGeAlD
Dabrafenib—ABCB1—hematopoietic system—hematologic cancer	0.000222	0.00676	CbGeAlD
Dabrafenib—CYP3A4—blood—hematologic cancer	0.000208	0.00633	CbGeAlD
Dabrafenib—ABCG2—lymph node—hematologic cancer	0.000179	0.00544	CbGeAlD
Dabrafenib—ABCB1—gonad—hematologic cancer	0.000169	0.00514	CbGeAlD
Dabrafenib—ABCB1—blood—hematologic cancer	0.000147	0.00448	CbGeAlD
Dabrafenib—ABCB1—bone marrow—hematologic cancer	0.000142	0.00433	CbGeAlD
Dabrafenib—ABCB1—lung—hematologic cancer	0.000129	0.00393	CbGeAlD
Dabrafenib—ABCB1—testis—hematologic cancer	0.000122	0.0037	CbGeAlD
Dabrafenib—ABCB1—lymph node—hematologic cancer	8.83e-05	0.00268	CbGeAlD
Dabrafenib—Angiopathy—Methotrexate—hematologic cancer	1.46e-05	9.65e-05	CcSEcCtD
Dabrafenib—Vomiting—Irinotecan—hematologic cancer	1.46e-05	9.65e-05	CcSEcCtD
Dabrafenib—Vomiting—Mitoxantrone—hematologic cancer	1.46e-05	9.65e-05	CcSEcCtD
Dabrafenib—Immune system disorder—Methotrexate—hematologic cancer	1.45e-05	9.61e-05	CcSEcCtD
Dabrafenib—Nausea—Alitretinoin—hematologic cancer	1.45e-05	9.6e-05	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—hematologic cancer	1.45e-05	9.59e-05	CcSEcCtD
Dabrafenib—Hypertension—Prednisone—hematologic cancer	1.44e-05	9.57e-05	CcSEcCtD
Dabrafenib—Rash—Mitoxantrone—hematologic cancer	1.44e-05	9.57e-05	CcSEcCtD
Dabrafenib—Rash—Irinotecan—hematologic cancer	1.44e-05	9.57e-05	CcSEcCtD
Dabrafenib—Dermatitis—Mitoxantrone—hematologic cancer	1.44e-05	9.56e-05	CcSEcCtD
Dabrafenib—Dermatitis—Irinotecan—hematologic cancer	1.44e-05	9.56e-05	CcSEcCtD
Dabrafenib—Chills—Methotrexate—hematologic cancer	1.44e-05	9.55e-05	CcSEcCtD
Dabrafenib—Headache—Irinotecan—hematologic cancer	1.43e-05	9.5e-05	CcSEcCtD
Dabrafenib—Headache—Mitoxantrone—hematologic cancer	1.43e-05	9.5e-05	CcSEcCtD
Dabrafenib—Nausea—Ifosfamide—hematologic cancer	1.43e-05	9.49e-05	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Betamethasone—hematologic cancer	1.43e-05	9.46e-05	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	1.43e-05	9.46e-05	CcSEcCtD
Dabrafenib—Arthralgia—Prednisone—hematologic cancer	1.42e-05	9.43e-05	CcSEcCtD
Dabrafenib—Myalgia—Prednisone—hematologic cancer	1.42e-05	9.43e-05	CcSEcCtD
Dabrafenib—Diarrhoea—Cisplatin—hematologic cancer	1.42e-05	9.42e-05	CcSEcCtD
Dabrafenib—Alopecia—Methotrexate—hematologic cancer	1.42e-05	9.4e-05	CcSEcCtD
Dabrafenib—Vomiting—Gemcitabine—hematologic cancer	1.42e-05	9.4e-05	CcSEcCtD
Dabrafenib—Insomnia—Dexamethasone—hematologic cancer	1.42e-05	9.39e-05	CcSEcCtD
Dabrafenib—Insomnia—Betamethasone—hematologic cancer	1.42e-05	9.39e-05	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	1.41e-05	9.37e-05	CcSEcCtD
Dabrafenib—Mental disorder—Methotrexate—hematologic cancer	1.41e-05	9.32e-05	CcSEcCtD
Dabrafenib—Rash—Gemcitabine—hematologic cancer	1.41e-05	9.32e-05	CcSEcCtD
Dabrafenib—Dermatitis—Gemcitabine—hematologic cancer	1.4e-05	9.31e-05	CcSEcCtD
Dabrafenib—Eye disorder—Epirubicin—hematologic cancer	1.4e-05	9.3e-05	CcSEcCtD
Dabrafenib—Hypersensitivity—Etoposide—hematologic cancer	1.4e-05	9.3e-05	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—hematologic cancer	1.4e-05	9.26e-05	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—hematologic cancer	1.4e-05	9.26e-05	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—hematologic cancer	1.4e-05	9.26e-05	CcSEcCtD
Dabrafenib—Headache—Gemcitabine—hematologic cancer	1.4e-05	9.26e-05	CcSEcCtD
Dabrafenib—Nausea—Vincristine—hematologic cancer	1.4e-05	9.25e-05	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—hematologic cancer	1.39e-05	9.21e-05	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisolone—hematologic cancer	1.38e-05	9.17e-05	CcSEcCtD
Dabrafenib—Urinary tract disorder—Doxorubicin—hematologic cancer	1.37e-05	9.1e-05	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—hematologic cancer	1.37e-05	9.08e-05	CcSEcCtD
Dabrafenib—Asthenia—Etoposide—hematologic cancer	1.37e-05	9.05e-05	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—hematologic cancer	1.37e-05	9.05e-05	CcSEcCtD
Dabrafenib—Body temperature increased—Triamcinolone—hematologic cancer	1.37e-05	9.05e-05	CcSEcCtD
Dabrafenib—Oedema—Prednisone—hematologic cancer	1.36e-05	9.04e-05	CcSEcCtD
Dabrafenib—Angiopathy—Epirubicin—hematologic cancer	1.36e-05	9.03e-05	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—hematologic cancer	1.36e-05	9.03e-05	CcSEcCtD
Dabrafenib—Decreased appetite—Betamethasone—hematologic cancer	1.36e-05	9.03e-05	CcSEcCtD
Dabrafenib—Decreased appetite—Dexamethasone—hematologic cancer	1.36e-05	9.03e-05	CcSEcCtD
Dabrafenib—Nausea—Mitoxantrone—hematologic cancer	1.36e-05	9.01e-05	CcSEcCtD
Dabrafenib—Nausea—Irinotecan—hematologic cancer	1.36e-05	9.01e-05	CcSEcCtD
Dabrafenib—Immune system disorder—Epirubicin—hematologic cancer	1.36e-05	8.99e-05	CcSEcCtD
Dabrafenib—Infection—Prednisone—hematologic cancer	1.36e-05	8.99e-05	CcSEcCtD
Dabrafenib—Mediastinal disorder—Epirubicin—hematologic cancer	1.35e-05	8.97e-05	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Dexamethasone—hematologic cancer	1.35e-05	8.97e-05	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Betamethasone—hematologic cancer	1.35e-05	8.97e-05	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—hematologic cancer	1.35e-05	8.96e-05	CcSEcCtD
Dabrafenib—Fatigue—Betamethasone—hematologic cancer	1.35e-05	8.95e-05	CcSEcCtD
Dabrafenib—Fatigue—Dexamethasone—hematologic cancer	1.35e-05	8.95e-05	CcSEcCtD
Dabrafenib—Chills—Epirubicin—hematologic cancer	1.35e-05	8.93e-05	CcSEcCtD
Dabrafenib—Pruritus—Etoposide—hematologic cancer	1.35e-05	8.93e-05	CcSEcCtD
Dabrafenib—Arrhythmia—Epirubicin—hematologic cancer	1.34e-05	8.89e-05	CcSEcCtD
Dabrafenib—Nervous system disorder—Prednisone—hematologic cancer	1.34e-05	8.87e-05	CcSEcCtD
Dabrafenib—Alopecia—Epirubicin—hematologic cancer	1.33e-05	8.8e-05	CcSEcCtD
Dabrafenib—Skin disorder—Prednisone—hematologic cancer	1.33e-05	8.79e-05	CcSEcCtD
Dabrafenib—Nausea—Gemcitabine—hematologic cancer	1.32e-05	8.78e-05	CcSEcCtD
Dabrafenib—Vomiting—Cisplatin—hematologic cancer	1.32e-05	8.76e-05	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisone—hematologic cancer	1.32e-05	8.74e-05	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—hematologic cancer	1.32e-05	8.73e-05	CcSEcCtD
Dabrafenib—Mental disorder—Epirubicin—hematologic cancer	1.32e-05	8.72e-05	CcSEcCtD
Dabrafenib—Rash—Cisplatin—hematologic cancer	1.31e-05	8.69e-05	CcSEcCtD
Dabrafenib—Dermatitis—Cisplatin—hematologic cancer	1.31e-05	8.68e-05	CcSEcCtD
Dabrafenib—Erythema—Epirubicin—hematologic cancer	1.31e-05	8.67e-05	CcSEcCtD
Dabrafenib—Malnutrition—Epirubicin—hematologic cancer	1.31e-05	8.67e-05	CcSEcCtD
Dabrafenib—Diarrhoea—Etoposide—hematologic cancer	1.3e-05	8.63e-05	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—hematologic cancer	1.3e-05	8.61e-05	CcSEcCtD
Dabrafenib—Anaemia—Methotrexate—hematologic cancer	1.29e-05	8.56e-05	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.28e-05	8.49e-05	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Betamethasone—hematologic cancer	1.28e-05	8.49e-05	CcSEcCtD
Dabrafenib—Hypersensitivity—Triamcinolone—hematologic cancer	1.27e-05	8.43e-05	CcSEcCtD
Dabrafenib—Back pain—Epirubicin—hematologic cancer	1.27e-05	8.38e-05	CcSEcCtD
Dabrafenib—Angiopathy—Doxorubicin—hematologic cancer	1.26e-05	8.36e-05	CcSEcCtD
Dabrafenib—Dizziness—Etoposide—hematologic cancer	1.26e-05	8.34e-05	CcSEcCtD
Dabrafenib—Muscle spasms—Epirubicin—hematologic cancer	1.26e-05	8.33e-05	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—hematologic cancer	1.26e-05	8.32e-05	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—hematologic cancer	1.25e-05	8.3e-05	CcSEcCtD
Dabrafenib—Leukopenia—Methotrexate—hematologic cancer	1.25e-05	8.29e-05	CcSEcCtD
Dabrafenib—Chills—Doxorubicin—hematologic cancer	1.25e-05	8.27e-05	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.24e-05	8.24e-05	CcSEcCtD
Dabrafenib—Dizziness—Prednisolone—hematologic cancer	1.24e-05	8.23e-05	CcSEcCtD
Dabrafenib—Arrhythmia—Doxorubicin—hematologic cancer	1.24e-05	8.23e-05	CcSEcCtD
Dabrafenib—Asthenia—Triamcinolone—hematologic cancer	1.24e-05	8.21e-05	CcSEcCtD
Dabrafenib—Body temperature increased—Dexamethasone—hematologic cancer	1.24e-05	8.21e-05	CcSEcCtD
Dabrafenib—Abdominal pain—Dexamethasone—hematologic cancer	1.24e-05	8.21e-05	CcSEcCtD
Dabrafenib—Abdominal pain—Betamethasone—hematologic cancer	1.24e-05	8.21e-05	CcSEcCtD
Dabrafenib—Body temperature increased—Betamethasone—hematologic cancer	1.24e-05	8.21e-05	CcSEcCtD
Dabrafenib—Nausea—Cisplatin—hematologic cancer	1.23e-05	8.18e-05	CcSEcCtD
Dabrafenib—Insomnia—Prednisone—hematologic cancer	1.23e-05	8.18e-05	CcSEcCtD
Dabrafenib—Vision blurred—Epirubicin—hematologic cancer	1.23e-05	8.17e-05	CcSEcCtD
Dabrafenib—Alopecia—Doxorubicin—hematologic cancer	1.23e-05	8.14e-05	CcSEcCtD
Dabrafenib—Pruritus—Triamcinolone—hematologic cancer	1.22e-05	8.1e-05	CcSEcCtD
Dabrafenib—Cough—Methotrexate—hematologic cancer	1.22e-05	8.08e-05	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—hematologic cancer	1.22e-05	8.07e-05	CcSEcCtD
Dabrafenib—Vomiting—Etoposide—hematologic cancer	1.21e-05	8.02e-05	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—hematologic cancer	1.21e-05	8.02e-05	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—hematologic cancer	1.21e-05	8.02e-05	CcSEcCtD
Dabrafenib—Anaemia—Epirubicin—hematologic cancer	1.21e-05	8.01e-05	CcSEcCtD
Dabrafenib—Rash—Etoposide—hematologic cancer	1.2e-05	7.96e-05	CcSEcCtD
Dabrafenib—Dermatitis—Etoposide—hematologic cancer	1.2e-05	7.95e-05	CcSEcCtD
Dabrafenib—Headache—Etoposide—hematologic cancer	1.19e-05	7.91e-05	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—hematologic cancer	1.19e-05	7.88e-05	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—hematologic cancer	1.19e-05	7.88e-05	CcSEcCtD
Dabrafenib—Decreased appetite—Prednisone—hematologic cancer	1.19e-05	7.86e-05	CcSEcCtD
Dabrafenib—Rash—Prednisolone—hematologic cancer	1.18e-05	7.85e-05	CcSEcCtD
Dabrafenib—Dermatitis—Prednisolone—hematologic cancer	1.18e-05	7.84e-05	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.18e-05	7.83e-05	CcSEcCtD
Dabrafenib—Fatigue—Prednisone—hematologic cancer	1.18e-05	7.8e-05	CcSEcCtD
Dabrafenib—Headache—Prednisolone—hematologic cancer	1.18e-05	7.8e-05	CcSEcCtD
Dabrafenib—Leukopenia—Epirubicin—hematologic cancer	1.17e-05	7.76e-05	CcSEcCtD
Dabrafenib—Back pain—Doxorubicin—hematologic cancer	1.17e-05	7.76e-05	CcSEcCtD
Dabrafenib—Constipation—Prednisone—hematologic cancer	1.17e-05	7.73e-05	CcSEcCtD
Dabrafenib—Muscle spasms—Doxorubicin—hematologic cancer	1.16e-05	7.71e-05	CcSEcCtD
Dabrafenib—Dizziness—Triamcinolone—hematologic cancer	1.14e-05	7.57e-05	CcSEcCtD
Dabrafenib—Cough—Epirubicin—hematologic cancer	1.14e-05	7.56e-05	CcSEcCtD
Dabrafenib—Vision blurred—Doxorubicin—hematologic cancer	1.14e-05	7.56e-05	CcSEcCtD
Dabrafenib—Infection—Methotrexate—hematologic cancer	1.13e-05	7.51e-05	CcSEcCtD
Dabrafenib—Nausea—Etoposide—hematologic cancer	1.13e-05	7.5e-05	CcSEcCtD
Dabrafenib—Hypertension—Epirubicin—hematologic cancer	1.13e-05	7.48e-05	CcSEcCtD
Dabrafenib—Asthenia—Dexamethasone—hematologic cancer	1.12e-05	7.45e-05	CcSEcCtD
Dabrafenib—Asthenia—Betamethasone—hematologic cancer	1.12e-05	7.45e-05	CcSEcCtD
Dabrafenib—Nervous system disorder—Methotrexate—hematologic cancer	1.12e-05	7.41e-05	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—hematologic cancer	1.12e-05	7.41e-05	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—hematologic cancer	1.12e-05	7.4e-05	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Prednisone—hematologic cancer	1.12e-05	7.4e-05	CcSEcCtD
Dabrafenib—Nausea—Prednisolone—hematologic cancer	1.12e-05	7.39e-05	CcSEcCtD
Dabrafenib—Arthralgia—Epirubicin—hematologic cancer	1.11e-05	7.38e-05	CcSEcCtD
Dabrafenib—Myalgia—Epirubicin—hematologic cancer	1.11e-05	7.38e-05	CcSEcCtD
Dabrafenib—Pruritus—Dexamethasone—hematologic cancer	1.11e-05	7.35e-05	CcSEcCtD
Dabrafenib—Pruritus—Betamethasone—hematologic cancer	1.11e-05	7.35e-05	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—hematologic cancer	1.11e-05	7.34e-05	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.11e-05	7.33e-05	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—hematologic cancer	1.1e-05	7.31e-05	CcSEcCtD
Dabrafenib—Vomiting—Triamcinolone—hematologic cancer	1.1e-05	7.28e-05	CcSEcCtD
Dabrafenib—Rash—Triamcinolone—hematologic cancer	1.09e-05	7.22e-05	CcSEcCtD
Dabrafenib—Dry mouth—Epirubicin—hematologic cancer	1.09e-05	7.22e-05	CcSEcCtD
Dabrafenib—Dermatitis—Triamcinolone—hematologic cancer	1.09e-05	7.21e-05	CcSEcCtD
Dabrafenib—Leukopenia—Doxorubicin—hematologic cancer	1.08e-05	7.18e-05	CcSEcCtD
Dabrafenib—Headache—Triamcinolone—hematologic cancer	1.08e-05	7.17e-05	CcSEcCtD
Dabrafenib—Abdominal pain—Prednisone—hematologic cancer	1.08e-05	7.15e-05	CcSEcCtD
Dabrafenib—Body temperature increased—Prednisone—hematologic cancer	1.08e-05	7.15e-05	CcSEcCtD
Dabrafenib—Diarrhoea—Betamethasone—hematologic cancer	1.07e-05	7.11e-05	CcSEcCtD
Dabrafenib—Diarrhoea—Dexamethasone—hematologic cancer	1.07e-05	7.11e-05	CcSEcCtD
Dabrafenib—Oedema—Epirubicin—hematologic cancer	1.07e-05	7.07e-05	CcSEcCtD
Dabrafenib—Hypotension—Methotrexate—hematologic cancer	1.07e-05	7.06e-05	CcSEcCtD
Dabrafenib—Infection—Epirubicin—hematologic cancer	1.06e-05	7.03e-05	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—hematologic cancer	1.06e-05	7e-05	CcSEcCtD
Dabrafenib—Nervous system disorder—Epirubicin—hematologic cancer	1.05e-05	6.94e-05	CcSEcCtD
Dabrafenib—Thrombocytopenia—Epirubicin—hematologic cancer	1.05e-05	6.93e-05	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—hematologic cancer	1.04e-05	6.92e-05	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.04e-05	6.89e-05	CcSEcCtD
Dabrafenib—Skin disorder—Epirubicin—hematologic cancer	1.04e-05	6.87e-05	CcSEcCtD
Dabrafenib—Dizziness—Betamethasone—hematologic cancer	1.04e-05	6.87e-05	CcSEcCtD
Dabrafenib—Dizziness—Dexamethasone—hematologic cancer	1.04e-05	6.87e-05	CcSEcCtD
Dabrafenib—Hyperhidrosis—Epirubicin—hematologic cancer	1.03e-05	6.84e-05	CcSEcCtD
Dabrafenib—Insomnia—Methotrexate—hematologic cancer	1.03e-05	6.84e-05	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—hematologic cancer	1.03e-05	6.83e-05	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—hematologic cancer	1.03e-05	6.83e-05	CcSEcCtD
Dabrafenib—Nausea—Triamcinolone—hematologic cancer	1.03e-05	6.8e-05	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.02e-05	6.78e-05	CcSEcCtD
Dabrafenib—Dry mouth—Doxorubicin—hematologic cancer	1.01e-05	6.68e-05	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisone—hematologic cancer	1.01e-05	6.66e-05	CcSEcCtD
Dabrafenib—Hypotension—Epirubicin—hematologic cancer	9.97e-06	6.61e-05	CcSEcCtD
Dabrafenib—Vomiting—Dexamethasone—hematologic cancer	9.96e-06	6.6e-05	CcSEcCtD
Dabrafenib—Vomiting—Betamethasone—hematologic cancer	9.96e-06	6.6e-05	CcSEcCtD
Dabrafenib—Decreased appetite—Methotrexate—hematologic cancer	9.91e-06	6.57e-05	CcSEcCtD
Dabrafenib—Rash—Betamethasone—hematologic cancer	9.88e-06	6.55e-05	CcSEcCtD
Dabrafenib—Rash—Dexamethasone—hematologic cancer	9.88e-06	6.55e-05	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—hematologic cancer	9.88e-06	6.55e-05	CcSEcCtD
Dabrafenib—Dermatitis—Dexamethasone—hematologic cancer	9.87e-06	6.54e-05	CcSEcCtD
Dabrafenib—Dermatitis—Betamethasone—hematologic cancer	9.87e-06	6.54e-05	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Methotrexate—hematologic cancer	9.85e-06	6.53e-05	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—hematologic cancer	9.83e-06	6.52e-05	CcSEcCtD
Dabrafenib—Headache—Dexamethasone—hematologic cancer	9.82e-06	6.51e-05	CcSEcCtD
Dabrafenib—Headache—Betamethasone—hematologic cancer	9.82e-06	6.51e-05	CcSEcCtD
Dabrafenib—Infection—Doxorubicin—hematologic cancer	9.81e-06	6.5e-05	CcSEcCtD
Dabrafenib—Asthenia—Prednisone—hematologic cancer	9.79e-06	6.49e-05	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Epirubicin—hematologic cancer	9.72e-06	6.44e-05	CcSEcCtD
Dabrafenib—Nervous system disorder—Doxorubicin—hematologic cancer	9.69e-06	6.42e-05	CcSEcCtD
Dabrafenib—Thrombocytopenia—Doxorubicin—hematologic cancer	9.67e-06	6.41e-05	CcSEcCtD
Dabrafenib—Pruritus—Prednisone—hematologic cancer	9.66e-06	6.4e-05	CcSEcCtD
Dabrafenib—Insomnia—Epirubicin—hematologic cancer	9.65e-06	6.4e-05	CcSEcCtD
Dabrafenib—Skin disorder—Doxorubicin—hematologic cancer	9.59e-06	6.36e-05	CcSEcCtD
Dabrafenib—Hyperhidrosis—Doxorubicin—hematologic cancer	9.55e-06	6.33e-05	CcSEcCtD
Dabrafenib—Diarrhoea—Prednisone—hematologic cancer	9.34e-06	6.19e-05	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methotrexate—hematologic cancer	9.33e-06	6.18e-05	CcSEcCtD
Dabrafenib—Nausea—Dexamethasone—hematologic cancer	9.31e-06	6.17e-05	CcSEcCtD
Dabrafenib—Nausea—Betamethasone—hematologic cancer	9.31e-06	6.17e-05	CcSEcCtD
Dabrafenib—Decreased appetite—Epirubicin—hematologic cancer	9.28e-06	6.15e-05	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—hematologic cancer	9.23e-06	6.12e-05	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Epirubicin—hematologic cancer	9.22e-06	6.11e-05	CcSEcCtD
Dabrafenib—Fatigue—Epirubicin—hematologic cancer	9.2e-06	6.1e-05	CcSEcCtD
Dabrafenib—Constipation—Epirubicin—hematologic cancer	9.13e-06	6.05e-05	CcSEcCtD
Dabrafenib—Dizziness—Prednisone—hematologic cancer	9.02e-06	5.98e-05	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—hematologic cancer	9.02e-06	5.98e-05	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—hematologic cancer	9.02e-06	5.98e-05	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	9e-06	5.96e-05	CcSEcCtD
Dabrafenib—Insomnia—Doxorubicin—hematologic cancer	8.93e-06	5.92e-05	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Epirubicin—hematologic cancer	8.73e-06	5.78e-05	CcSEcCtD
Dabrafenib—Vomiting—Prednisone—hematologic cancer	8.68e-06	5.75e-05	CcSEcCtD
Dabrafenib—Rash—Prednisone—hematologic cancer	8.6e-06	5.7e-05	CcSEcCtD
Dabrafenib—Dermatitis—Prednisone—hematologic cancer	8.6e-06	5.7e-05	CcSEcCtD
Dabrafenib—Decreased appetite—Doxorubicin—hematologic cancer	8.59e-06	5.69e-05	CcSEcCtD
Dabrafenib—Headache—Prednisone—hematologic cancer	8.55e-06	5.67e-05	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	8.53e-06	5.65e-05	CcSEcCtD
Dabrafenib—Fatigue—Doxorubicin—hematologic cancer	8.51e-06	5.64e-05	CcSEcCtD
Dabrafenib—Constipation—Doxorubicin—hematologic cancer	8.45e-06	5.6e-05	CcSEcCtD
Dabrafenib—Abdominal pain—Epirubicin—hematologic cancer	8.44e-06	5.59e-05	CcSEcCtD
Dabrafenib—Body temperature increased—Epirubicin—hematologic cancer	8.44e-06	5.59e-05	CcSEcCtD
Dabrafenib—Hypersensitivity—Methotrexate—hematologic cancer	8.4e-06	5.57e-05	CcSEcCtD
Dabrafenib—Asthenia—Methotrexate—hematologic cancer	8.18e-06	5.42e-05	CcSEcCtD
Dabrafenib—Nausea—Prednisone—hematologic cancer	8.11e-06	5.37e-05	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—hematologic cancer	8.08e-06	5.35e-05	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—hematologic cancer	8.07e-06	5.35e-05	CcSEcCtD
Dabrafenib—Hypersensitivity—Epirubicin—hematologic cancer	7.86e-06	5.21e-05	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—hematologic cancer	7.81e-06	5.17e-05	CcSEcCtD
Dabrafenib—Abdominal pain—Doxorubicin—hematologic cancer	7.81e-06	5.17e-05	CcSEcCtD
Dabrafenib—Diarrhoea—Methotrexate—hematologic cancer	7.8e-06	5.17e-05	CcSEcCtD
Dabrafenib—Asthenia—Epirubicin—hematologic cancer	7.66e-06	5.08e-05	CcSEcCtD
Dabrafenib—Pruritus—Epirubicin—hematologic cancer	7.55e-06	5e-05	CcSEcCtD
Dabrafenib—Dizziness—Methotrexate—hematologic cancer	7.54e-06	5e-05	CcSEcCtD
Dabrafenib—Diarrhoea—Epirubicin—hematologic cancer	7.3e-06	4.84e-05	CcSEcCtD
Dabrafenib—Hypersensitivity—Doxorubicin—hematologic cancer	7.28e-06	4.82e-05	CcSEcCtD
Dabrafenib—Vomiting—Methotrexate—hematologic cancer	7.25e-06	4.81e-05	CcSEcCtD
Dabrafenib—Rash—Methotrexate—hematologic cancer	7.19e-06	4.77e-05	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—hematologic cancer	7.18e-06	4.76e-05	CcSEcCtD
Dabrafenib—Headache—Methotrexate—hematologic cancer	7.15e-06	4.74e-05	CcSEcCtD
Dabrafenib—Asthenia—Doxorubicin—hematologic cancer	7.09e-06	4.7e-05	CcSEcCtD
Dabrafenib—Dizziness—Epirubicin—hematologic cancer	7.06e-06	4.68e-05	CcSEcCtD
Dabrafenib—Pruritus—Doxorubicin—hematologic cancer	6.99e-06	4.63e-05	CcSEcCtD
Dabrafenib—Vomiting—Epirubicin—hematologic cancer	6.79e-06	4.5e-05	CcSEcCtD
Dabrafenib—Nausea—Methotrexate—hematologic cancer	6.77e-06	4.49e-05	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—hematologic cancer	6.76e-06	4.48e-05	CcSEcCtD
Dabrafenib—Rash—Epirubicin—hematologic cancer	6.73e-06	4.46e-05	CcSEcCtD
Dabrafenib—Dermatitis—Epirubicin—hematologic cancer	6.72e-06	4.46e-05	CcSEcCtD
Dabrafenib—Headache—Epirubicin—hematologic cancer	6.69e-06	4.43e-05	CcSEcCtD
Dabrafenib—Dizziness—Doxorubicin—hematologic cancer	6.53e-06	4.33e-05	CcSEcCtD
Dabrafenib—Nausea—Epirubicin—hematologic cancer	6.34e-06	4.2e-05	CcSEcCtD
Dabrafenib—Vomiting—Doxorubicin—hematologic cancer	6.28e-06	4.16e-05	CcSEcCtD
Dabrafenib—Rash—Doxorubicin—hematologic cancer	6.23e-06	4.13e-05	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—hematologic cancer	6.22e-06	4.12e-05	CcSEcCtD
Dabrafenib—Headache—Doxorubicin—hematologic cancer	6.19e-06	4.1e-05	CcSEcCtD
Dabrafenib—Nausea—Doxorubicin—hematologic cancer	5.87e-06	3.89e-05	CcSEcCtD
Dabrafenib—RAF1—Immune System—MTOR—hematologic cancer	1.44e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CB—hematologic cancer	1.44e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—hematologic cancer	1.44e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.44e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AGRN—hematologic cancer	1.43e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MAPK3—hematologic cancer	1.42e-06	1.31e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—JAK2—hematologic cancer	1.42e-06	1.31e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SDC1—hematologic cancer	1.42e-06	1.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PDGFB—hematologic cancer	1.41e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	1.41e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—JAK2—hematologic cancer	1.4e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HRAS—hematologic cancer	1.4e-06	1.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—hematologic cancer	1.4e-06	1.29e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MDM2—hematologic cancer	1.39e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CD44—hematologic cancer	1.39e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NQO1—hematologic cancer	1.39e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—hematologic cancer	1.38e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—hematologic cancer	1.38e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TSC2—hematologic cancer	1.38e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CG—hematologic cancer	1.37e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—hematologic cancer	1.37e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MDM2—hematologic cancer	1.37e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.36e-06	1.26e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—IDH2—hematologic cancer	1.36e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HMMR—hematologic cancer	1.36e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.36e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1B—hematologic cancer	1.35e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTEN—hematologic cancer	1.35e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MTOR—hematologic cancer	1.35e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CB—hematologic cancer	1.35e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HRAS—hematologic cancer	1.34e-06	1.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—hematologic cancer	1.34e-06	1.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTOR—hematologic cancer	1.33e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CB—hematologic cancer	1.33e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—hematologic cancer	1.33e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—hematologic cancer	1.33e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGFR3—hematologic cancer	1.33e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—hematologic cancer	1.33e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK14—hematologic cancer	1.31e-06	1.21e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYCS—hematologic cancer	1.31e-06	1.21e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HSP90AA1—hematologic cancer	1.3e-06	1.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—JUN—hematologic cancer	1.29e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—EP300—hematologic cancer	1.29e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ESR1—hematologic cancer	1.29e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—hematologic cancer	1.28e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ARNTL—hematologic cancer	1.28e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	1.27e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FN1—hematologic cancer	1.27e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CREBBP—hematologic cancer	1.27e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CG—hematologic cancer	1.27e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1B—hematologic cancer	1.27e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BAD—hematologic cancer	1.26e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NFKBIA—hematologic cancer	1.26e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1B—hematologic cancer	1.25e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1A—hematologic cancer	1.25e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTEN—hematologic cancer	1.25e-06	1.15e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOTCH1—hematologic cancer	1.25e-06	1.15e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ACP5—hematologic cancer	1.24e-06	1.15e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CA9—hematologic cancer	1.24e-06	1.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—hematologic cancer	1.24e-06	1.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—hematologic cancer	1.24e-06	1.15e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—hematologic cancer	1.23e-06	1.14e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NCOR2—hematologic cancer	1.23e-06	1.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK8—hematologic cancer	1.22e-06	1.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CD80—hematologic cancer	1.22e-06	1.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CG—hematologic cancer	1.22e-06	1.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KIT—hematologic cancer	1.22e-06	1.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—NRAS—hematologic cancer	1.22e-06	1.13e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—hematologic cancer	1.21e-06	1.12e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CD44—hematologic cancer	1.21e-06	1.12e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NQO1—hematologic cancer	1.21e-06	1.12e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CD—hematologic cancer	1.21e-06	1.11e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—JUN—hematologic cancer	1.21e-06	1.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTPN11—hematologic cancer	1.2e-06	1.11e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—hematologic cancer	1.19e-06	1.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EP300—hematologic cancer	1.19e-06	1.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—hematologic cancer	1.19e-06	1.1e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CREBBP—hematologic cancer	1.18e-06	1.09e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CA—hematologic cancer	1.17e-06	1.09e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.17e-06	1.08e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1A—hematologic cancer	1.17e-06	1.08e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—IDH1—hematologic cancer	1.17e-06	1.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—MAPK3—hematologic cancer	1.17e-06	1.08e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTEN—hematologic cancer	1.17e-06	1.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CREB1—hematologic cancer	1.16e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SRC—hematologic cancer	1.16e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTP1—hematologic cancer	1.16e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1A—hematologic cancer	1.15e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TXN—hematologic cancer	1.15e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.15e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.15e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTEN—hematologic cancer	1.15e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BRAF—hematologic cancer	1.15e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYCS—hematologic cancer	1.14e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK8—hematologic cancer	1.14e-06	1.05e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3R1—hematologic cancer	1.14e-06	1.05e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HSP90AA1—hematologic cancer	1.14e-06	1.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL2—hematologic cancer	1.13e-06	1.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6R—hematologic cancer	1.13e-06	1.05e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.13e-06	1.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CREBBP—hematologic cancer	1.13e-06	1.04e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.12e-06	1.03e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CD—hematologic cancer	1.12e-06	1.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—hematologic cancer	1.12e-06	1.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NRAS—hematologic cancer	1.11e-06	1.03e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EP300—hematologic cancer	1.11e-06	1.03e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—hematologic cancer	1.1e-06	1.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EP300—hematologic cancer	1.1e-06	1.02e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCB1—hematologic cancer	1.09e-06	1.01e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HRAS—hematologic cancer	1.09e-06	1e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.09e-06	1e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SRC—hematologic cancer	1.08e-06	9.99e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAP2K1—hematologic cancer	1.08e-06	9.96e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CD—hematologic cancer	1.07e-06	9.9e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SRC—hematologic cancer	1.07e-06	9.87e-06	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK3—hematologic cancer	1.07e-06	9.85e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NCOR1—hematologic cancer	1.06e-06	9.82e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTM1—hematologic cancer	1.06e-06	9.82e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.06e-06	9.76e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.06e-06	9.76e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3R1—hematologic cancer	1.05e-06	9.75e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—hematologic cancer	1.05e-06	9.73e-06	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CB—hematologic cancer	1.05e-06	9.72e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—hematologic cancer	1.05e-06	9.69e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—hematologic cancer	1.04e-06	9.64e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NRAS—hematologic cancer	1.04e-06	9.61e-06	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—hematologic cancer	1.04e-06	9.61e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—hematologic cancer	1.03e-06	9.52e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALOX5—hematologic cancer	1.03e-06	9.51e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NRAS—hematologic cancer	1.03e-06	9.5e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGF2—hematologic cancer	1.03e-06	9.48e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3R1—hematologic cancer	1.01e-06	9.35e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTP1—hematologic cancer	1.01e-06	9.31e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NUP98—hematologic cancer	9.96e-07	9.21e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK3—hematologic cancer	9.96e-07	9.21e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MAPK3—hematologic cancer	9.84e-07	9.1e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JAK2—hematologic cancer	9.83e-07	9.08e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CB—hematologic cancer	9.74e-07	9e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—hematologic cancer	9.69e-07	8.95e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NCOA3—hematologic cancer	9.67e-07	8.94e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ADCY7—hematologic cancer	9.67e-07	8.94e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—hematologic cancer	9.67e-07	8.93e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CA—hematologic cancer	9.63e-07	8.9e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NUP214—hematologic cancer	9.6e-07	8.88e-06	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—hematologic cancer	9.59e-07	8.87e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MDM2—hematologic cancer	9.59e-07	8.87e-06	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—hematologic cancer	9.58e-07	8.85e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—hematologic cancer	9.57e-07	8.85e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—hematologic cancer	9.55e-07	8.83e-06	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CA—hematologic cancer	9.54e-07	8.82e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCG2—hematologic cancer	9.41e-07	8.7e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTR—hematologic cancer	9.41e-07	8.7e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—hematologic cancer	9.39e-07	8.67e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MTOR—hematologic cancer	9.33e-07	8.63e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CB—hematologic cancer	9.33e-07	8.63e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTM1—hematologic cancer	9.25e-07	8.55e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NCOR1—hematologic cancer	9.25e-07	8.55e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ENO2—hematologic cancer	9.23e-07	8.53e-06	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTEN—hematologic cancer	9.09e-07	8.4e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—hematologic cancer	8.95e-07	8.27e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTT1—hematologic cancer	8.95e-07	8.27e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRAS—hematologic cancer	8.91e-07	8.24e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—hematologic cancer	8.84e-07	8.17e-06	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CA—hematologic cancer	8.8e-07	8.13e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1B—hematologic cancer	8.76e-07	8.1e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SDC1—hematologic cancer	8.75e-07	8.08e-06	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—EP300—hematologic cancer	8.67e-07	8.01e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—hematologic cancer	8.59e-07	7.93e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—hematologic cancer	8.57e-07	7.92e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—hematologic cancer	8.53e-07	7.88e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTEN—hematologic cancer	8.41e-07	7.78e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—hematologic cancer	8.36e-07	7.72e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JUN—hematologic cancer	8.34e-07	7.71e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.27e-07	7.64e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CA—hematologic cancer	8.22e-07	7.6e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—hematologic cancer	8.18e-07	7.56e-06	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HRAS—hematologic cancer	8.14e-07	7.53e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CA—hematologic cancer	8.13e-07	7.51e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1A—hematologic cancer	8.08e-07	7.47e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTEN—hematologic cancer	8.07e-07	7.45e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—EP300—hematologic cancer	8.02e-07	7.42e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—hematologic cancer	7.96e-07	7.35e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK8—hematologic cancer	7.89e-07	7.29e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CG—hematologic cancer	7.89e-07	7.29e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—hematologic cancer	7.87e-07	7.27e-06	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—hematologic cancer	7.79e-07	7.2e-06	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—hematologic cancer	7.79e-07	7.2e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EP300—hematologic cancer	7.69e-07	7.11e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRAS—hematologic cancer	7.61e-07	7.03e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HRAS—hematologic cancer	7.52e-07	6.95e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SRC—hematologic cancer	7.48e-07	6.91e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NQO1—hematologic cancer	7.44e-07	6.87e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CD44—hematologic cancer	7.44e-07	6.87e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CREBBP—hematologic cancer	7.31e-07	6.76e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—hematologic cancer	7.29e-07	6.73e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—hematologic cancer	7.28e-07	6.73e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—hematologic cancer	7.21e-07	6.67e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NRAS—hematologic cancer	7.2e-07	6.65e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—hematologic cancer	7.2e-07	6.65e-06	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—hematologic cancer	7.19e-07	6.64e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYCS—hematologic cancer	7.04e-07	6.5e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	6.99e-07	6.46e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CD—hematologic cancer	6.93e-07	6.41e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK3—hematologic cancer	6.89e-07	6.37e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CG—hematologic cancer	6.87e-07	6.35e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—hematologic cancer	6.84e-07	6.32e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—hematologic cancer	6.72e-07	6.21e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—hematologic cancer	6.7e-07	6.19e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—hematologic cancer	6.69e-07	6.18e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—hematologic cancer	6.64e-07	6.13e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3R1—hematologic cancer	6.55e-07	6.05e-06	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CA—hematologic cancer	6.41e-07	5.92e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CREBBP—hematologic cancer	6.37e-07	5.89e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTP1—hematologic cancer	6.2e-07	5.73e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—hematologic cancer	6.19e-07	5.72e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CB—hematologic cancer	6.04e-07	5.58e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CD—hematologic cancer	6.04e-07	5.58e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—hematologic cancer	5.96e-07	5.51e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CA—hematologic cancer	5.94e-07	5.49e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCB1—hematologic cancer	5.87e-07	5.43e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3R1—hematologic cancer	5.7e-07	5.27e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NCOR1—hematologic cancer	5.7e-07	5.27e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTM1—hematologic cancer	5.7e-07	5.27e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CA—hematologic cancer	5.69e-07	5.26e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—hematologic cancer	5.51e-07	5.09e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRAS—hematologic cancer	5.26e-07	4.87e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CB—hematologic cancer	5.26e-07	4.87e-06	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—hematologic cancer	5.24e-07	4.84e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTEN—hematologic cancer	5.22e-07	4.83e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—hematologic cancer	5.04e-07	4.66e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—hematologic cancer	5.04e-07	4.66e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—EP300—hematologic cancer	4.98e-07	4.6e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—hematologic cancer	4.85e-07	4.48e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—hematologic cancer	4.65e-07	4.3e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTEN—hematologic cancer	4.55e-07	4.2e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—EP300—hematologic cancer	4.34e-07	4.01e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	4.23e-07	3.91e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CREBBP—hematologic cancer	3.92e-07	3.63e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	3.72e-07	3.44e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CA—hematologic cancer	3.68e-07	3.4e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—hematologic cancer	3.67e-07	3.39e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	3.51e-07	3.25e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	3.24e-07	3e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CA—hematologic cancer	3.21e-07	2.97e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—hematologic cancer	3.01e-07	2.78e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTEN—hematologic cancer	2.8e-07	2.59e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—EP300—hematologic cancer	2.67e-07	2.47e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—hematologic cancer	2.62e-07	2.42e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.98e-07	1.83e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—hematologic cancer	1.62e-07	1.49e-06	CbGpPWpGaD
